Viewing data from:

DEFLAZACORT

ANDA

DEFLAZACORT | A220709 | CARNEGIE PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: EMFLAZA(TE code: AB)

API Supply Chain5 active DMFs1 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SYMBIOTEC PHARMALAB PRIVATE LTDDEFLAZACORT MICRONIZED

DMF 246912011

STERLING SPADEFLAZACORT

DMF 303132016

TIANJIN TIANYAO PHARMACEUTICALS CO LTDDEFLAZACORT BULK API

DMF 355352021

NEWCHEM SPADEFLAZACORT

DMF 383572023

CORAL DRUGS PRIVATE LTDDEFLAZACORT

DMF 389362023

SCHERING AGInactiveDEFLAZACORT

DMF 49221983

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 22.75MG/ML

0 patents0 exclusivities▴

SUSPENSION;ORAL | Approved: May 28, 2026

No patent or exclusivity listings for this strength.

Change History (1)

Recent changes detected for this application.

ADDED7/1/2026

Deflazacort (deflazacort) product record added to FDA database under NDA 220709, applicant Carnegie.

New: New record